These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25506936)

  • 21. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
    Perez-Iglesias R; Vazquez-Barquero JL; Amado JA; Berja A; Garcia-Unzueta MT; Pelayo-Terán JM; Carrasco-Marín E; Mata I; Crespo-Facorro B
    J Clin Psychopharmacol; 2008 Jun; 28(3):289-95. PubMed ID: 18480685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight gain during long-term treatment with olanzapine: a case series.
    Haberfellner EM; Rittmannsberger H
    Int Clin Psychopharmacol; 2004 Jul; 19(4):251-3. PubMed ID: 15201573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
    Saddichha S; Ameen S; Akhtar S
    J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study.
    Milano W; Grillo F; Del Mastro A; De Rosa M; Sanseverino B; Petrella C; Capasso A
    Adv Ther; 2007; 24(1):123-34. PubMed ID: 17526469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility of male wild type mouse strains to antipsychotic-induced weight gain.
    Zapata RC; Osborn O
    Physiol Behav; 2020 Jun; 220():112859. PubMed ID: 32156556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine.
    Santarelli DM; Liu B; Duncan CE; Beveridge NJ; Tooney PA; Schofield PR; Cairns MJ
    Psychopharmacology (Berl); 2013 May; 227(1):67-78. PubMed ID: 23318695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats.
    Evers SS; Calcagnoli F; van Dijk G; Scheurink AJ
    Pharmacol Biochem Behav; 2010 Nov; 97(1):163-9. PubMed ID: 20570692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.
    Mukundan A; Faulkner G; Cohn T; Remington G
    Cochrane Database Syst Rev; 2010 Dec; 2010(12):CD006629. PubMed ID: 21154372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypothalamic histamine H1 receptor-AMPK signaling time-dependently mediates olanzapine-induced hyperphagia and weight gain in female rats.
    He M; Zhang Q; Deng C; Wang H; Lian J; Huang XF
    Psychoneuroendocrinology; 2014 Apr; 42():153-64. PubMed ID: 24636512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The artificial sweetener acesulfame potassium affects the gut microbiome and body weight gain in CD-1 mice.
    Bian X; Chi L; Gao B; Tu P; Ru H; Lu K
    PLoS One; 2017; 12(6):e0178426. PubMed ID: 28594855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children.
    Bahr SM; Tyler BC; Wooldridge N; Butcher BD; Burns TL; Teesch LM; Oltman CL; Azcarate-Peril MA; Kirby JR; Calarge CA
    Transl Psychiatry; 2015 Oct; 5(10):e652. PubMed ID: 26440540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.
    Pouzet B; Mow T; Kreilgaard M; Velschow S
    Pharmacol Biochem Behav; 2003 Apr; 75(1):133-40. PubMed ID: 12759121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine-induced weight gain.
    Gupta S; Droney T; Al-Samarrai S; Keller P; Frank B
    Ann Clin Psychiatry; 1998 Mar; 10(1):39. PubMed ID: 9622049
    [No Abstract]   [Full Text] [Related]  

  • 35. Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
    Belanoff JK; Blasey CM; Clark RD; Roe RL
    Diabetes Obes Metab; 2010 Jun; 12(6):545-7. PubMed ID: 20518810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects.
    Skrede S; Martins L; Berge RK; Steen VM; López M; Fernø J
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):91-104. PubMed ID: 23919889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weight gain and hyperglycaemia associated with olanzapine.
    Riccitelli G; Baker N
    Aust N Z J Psychiatry; 2002 Apr; 36(2):270-1. PubMed ID: 11982558
    [No Abstract]   [Full Text] [Related]  

  • 38. Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
    Belanoff JK; Blasey CM; Clark RD; Roe RL
    Eur J Pharmacol; 2011 Mar; 655(1-3):117-20. PubMed ID: 21269600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.
    Arranz B; San L; Dueñas RM; Centeno M; Ramirez N; Salavert J; Del Moral E
    Hum Psychopharmacol; 2007 Jan; 22(1):11-5. PubMed ID: 17191265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine: review of safety 2008.
    Kantrowitz JT; Citrome L
    Expert Opin Drug Saf; 2008 Nov; 7(6):761-9. PubMed ID: 18983222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.